why choose us

First received: August 23, 2023

Clinical Trial: Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Pancreatic Ductal Adenocarcinoma

Study Type: INTERVENTIONAL


Official Title: A Phase 2 Study Evaluating the Efficacy of Anti-CD38 Antibody in Combination With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lu

Brief Summary: The goal of this clinical trial is to test the safety and tolerability of anti-CD38 monoclonal antibody (mAb), daratumumab, in combination with KRAS vaccine (Targovax TG-01/Stimulon QS-21) when given with anti-PD-1 (programmed cell death protein 1) mAb (nivolumab) in patients with advanced non-small cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma (PDAC).The main questions it aims to answer are:How well does daratumumab and nivolumab, when given with a vaccine, control or stop these types of…

Read more